Researchers have identified an important pathway that controls a set of protective genes in Parkinson's disease (PD). They report high levels of a regulatory protein, Bach1, in PD-affected brains and reduced disease symptoms after loss of Bach1 in preclinical models. Furthermore, in collaboration with vTv Therapeutics, they have identified a novel drug that inhibits Bach1 activity, helping to alleviate disease symptoms.